Latest Tax Rebates News

AnteoTech Ltd has received a $2.59 million cash rebate from the Australian Tax Office for its 2025 R&D activities, underscoring the success of its recent strategic initiatives.

Invex Therapeutics reports a significantly reduced net loss for FY25, driven by lower R&D costs after closing its Phase III trial, while advancing promising pre-clinical Alzheimer’s research through a collaboration with Tessara Therapeutics.

South Harz Potash Limited has bolstered its balance sheet through a combined A$2.39 million equity raise, positioning itself to pursue a dual-asset strategy targeting new critical minerals while preserving its core German potash project.

Blue Energy Limited has been awarded two significant Potential Commercial Areas in Queensland, boosting its contingent gas resources, while facing temporary suspension of pilot wells due to mechanical issues. The company is advancing regulatory approvals and exploring capital raising to support its growth.

Micro-X has landed a significant supply agreement with a top US healthcare provider for its Rover Plus mobile X-ray units, while progressing clinical trials and development milestones for its innovative CT imaging products.

Cobre Limited reports strong metallurgical results from its Botswana copper projects alongside a successful AU$1.68 million capital raising, setting the stage for upcoming resource estimates and environmental approvals.

Lincoln Minerals has identified multiple high-priority drill targets at its Minbrie Copper-Base Metals Project with drilling planned for late 2025, while its Kookaburra Graphite Project achieves battery-grade purity, underscoring the company’s strategic positioning in critical minerals.

Mont Royal Resources is progressing its merger with Commerce Resources to create a dual-listed Canadian critical metals developer, combining rare earth and lithium assets in Quebec.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

AnteoTech advances its battery technology with a new US joint development agreement and achieves significant performance milestones, while restructuring to sharpen its commercial focus.

Neurizon Therapeutics has made significant strides in developing its lead ALS drug candidate NUZ-001, unveiling a new liquid formulation and submitting a key regulatory response to the FDA. Clinical and preclinical data bolster hopes for broader neurodegenerative applications.

Neurizon Therapeutics has secured a $1.5 million loan against its expected 2025 R&D tax rebate, boosting liquidity without diluting shareholders. This strategic move supports ongoing development of its neurodegenerative disease treatments.